Buradasınız

Anasayfa » Content

MEME KANSERİNDE TİMİDİN İŞARETLEME İNDEKSİ VE Kİ-67 BOYANMASI: KLİNİK VE PATOLOJİK DEĞİŞKENLER İLE İLİŞKİLERİ

THYMIDINE LABELINGINDEX AND Ki-67 STAINING IN BREAST CANCER AND THEIR RELATIONSHIP TO CLINICAL AND PATHOLOGICAL VARIABLES

Journal Name:

  • İstanbul Tıp Fakültesi Dergisi

Publication Year:

  • 2004

Key Words:

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
İn Ihis study, two proliferation markers; i.e. thymidine labeliııg index (TLI) and Ki-67 scores of 32 brcast cancer patients were evaluated by assessing thc relationship wİth other prognostic parameters including lymph node status, nuclear-histopathologic grades, tumor size, estrogen-progesterone status and menopausal status. Both TLI values and Kİ67 scores werc correlated with nuclear and histologİc grades. Wl\ile indices of both proliferation markers were signifi-canüy lower in estrogen receptor positive patients than hormone negative patients, only TLI values were found to be significantly Iower in progesterone receptor positive patients. No other correlations or associations betwcen variables reached staîistical signifıcance. In conclusion, TLI and Ki-67 scores may be independent prognostic factors as nuclear grade and hormonal status.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-meme-kanserinde-timidin-isaretleme-indeksi-ki-67-boyanmasi-klinik-patolojik-degiskenler-ile-iliskileri.pdf
  • 2
92-98
  • English

REFERENCES

References: 

1. Quinn MC, VVrighf AN. The cünical assessment of proliferation and growih in human tumours: Evaluation of melhods and applicalions as prognostic variabies. J Pathol 1990; 160:93.
2. Scott RJ, Hail A, Hakianc JS et ai. Comparison of im-munohistochemical markers of celi proliferation wilh ex-
perimentally determined growth fraelion. J Pathol 1991; 165:173.
3. Amadori D and Silvestrini R. Prognostic and predietive value of thymidine labelling index in breast cancer. Breast Cancer Rcs Treat Î998; 51: 267.
4. Burger PC, Shibata T, Kleihues P. The use of the mono-clonal antibody Ki-67 in the identiiication of prolifcrat-ing cells: Application to surgical ncuropathology. Anı J Sur Pathol 1986; 10:611.
5. Brown DC, Gattcr KC. Monoclonal antibody Ki-67: its use in histopalhology. Histopathology 1990; 17:489.
6. Midulla C, Cencİ M, De Iorio P et al. DNA pioidy and TLI in associalion with other prognostic parameters in breast cancer. AnlicancerRes 1999; 19:38!.
7. Bamard NJ, HaLl PA, Lemoine. NR, Kadar N. ProLifera-tivcjndex in breast carcinomas determined in-situ by Ki-67 imınunostaining and its relationship to clinical and pathological variabies. J Pathol 1987; 152: 287.
8. Hasebe T, Mııkai K, Tsuda H, Ochiai A. New prognostic histological parameter of invasİve dııctal carcinoma of llıe breasi: clinicopathological significance of fibrolic fo-cus. Pathol Int 2000; 50: 263.
9. Fisher ER, Rcdmond C, Fisher B. Histologİc grading ot breast cancer. Pathol Annu 1980; 15: 239.
10. Black MM, Spccr FD, Nuclear strueture in cancer tis-sues. Surg Gynccol Obstet 1957; 105: 97.
11. Daidone MG and Silvestrini R. Prognostic and prediclive role of pıoiil'eration indices in adjuvant therapy of bıeasl cancer. JNatl Cancer Inst Monographs 2001; 2001: 27.
12. Del Bino G, Silvestrini R, Costa A, S et al. Morpfıologi-cal and clinical significance of celi kinetics in non-Hodg-kin's lymphonıas. Basic Appl Histochem 1986; 30:197,
13. Akerman M, Brandt L, Johnson A, Olsson H. Mİtolic activity in non-Hodgkin's lymphoma. Relation to the Kiel elassification and to prognosis. Br J Cancer 1987; 55: 219.
14. Ozmen V, Cabioglu N, Dolay K et al. Biological consid-erations in locally advanced breast cancer treated wilh anthracycline-based neoadjuvant chemotherapy: thymidine hıbelling index is an independent indicator of clinical outeome. Breast Cancer Res Treat 2001; 68: 147.
15. Pronzato P, Quciroİo P, Vecchio S et al. Thymidine labeling index analysis in early breast cancer patients ran-domized to receive perioperative chemotherapy. Oncolo-gy2001; 60: 88.
16. Araki K, Kimura M, Sakamoto K, Nishimura R, and Ak-agi Mİ. Significance of Ihe Iritiated thymidine labeling index in breast cancer. Jpn J Surg 15: 144-9(1985).
17. Hail PA. Rcwiew: Assessment of celi proliferation in histological material. J Clin Pathol 1990; 43: 184-92.
18. Gerdes J, Li L, Schlueter C el al. Immunobiochemical and molecular biologic characierization of the celi proliferation associated nuclear antigen that is defİned by monoclonal antibody Ki-67. Am.J Pathol 1991;138: 867.
19. VVolberg WH, Street WN, Mangasarian OL. Imporiancc of nuclear morphology in breast cancer prognosis. Clin Cancer Res 1999; 5: 3542 .
20. Picnta KJ and Coffey DS. Correlation of nuclear mor-phometry with progression of breast cancer. Cancer 1991; 68: 2012.
21. McGurrİtı JF, Doria MI Jr, Dawsoıı PJ et al. Assessment of lumor celi kinetics by immunohistochemistry in carcinoma of breast. Cancer 1987; 59: 1744.
Thymidine Labeling Tndex and Ki-67 Staining in Breast Cancer and Their Relationship to Clinical and Pathologieal Variabies
22. Yang Q, Mori I, Sakurai T, Yoshinıura G eî al. Correlation between nuclear grade and biological prognostic variabies in invasive breast cancer. Breast Cancer 200i; 8: 105.
23. Gerdes J, Lelle RJ, Pickartz H et al. Growth fraction in breast cancers determined in situ with monoclonal antibody Ki-67. J Clin Pathol 1986; 39: 977.
24. Riiymond WA, Leong AS-Y. The relationship between grovvtb fraetions and oestrogen receptors in human breast carcinoma, as determined by immunohistochemical staining. J Pathol 1989; 158: 203.
25. Correalc M, Abbate 1, Paradiso A ct al. pS2- a new eyto-solic protein recognized by monoclonal antiboclies as a marker of hormone sensitivity in breast cancer. Celi Bio-physics 1993; 22: 101.
26. Pichon MF, Pallud C, Brımet M, Milgrom E. Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer Res 1980; 40: 3357.
27. Cattoretti G, Rilke F, Andreola S et al. P53 expression in breast cancer. Int J Cancer 1988; 48: 4368.
28. Wrba F, Rciner A, Markis-Ritzingcr E et al. Prognostic significance of immunohistochemical parameters in breast carcinomas. Pathol Res Pract. 1988; 183: 277 .
29. Gebauer G, Fchm T, Lang N, Jöger W. Tumor sİ7.e, axil-iary lymph node status and steroid receptor expression in
breast cancer: prognostic relevance 5 years after surgery. Breast Cancer Res Treat 2002; 75:167.
30. Silveslrini R, Daidone MG, Luisi A et al. Celi proliferation in 3,800 node-negative breast cancers; consislcncy över time of biological and clinical information provided by 3H-thymidine labeling index. Int J Cancer 1997; 74: 122.
3). Meycr JS, Province MA. S-phase fraction and nuclear size in long term prognosis of patients with breast cancer. Cancer 1994; 74: 2287 .
32. Sigurdsson H, Baldetorp B, Borg A et al. İndicators of prognosis in node-negative breast cancer. N Engl i Med 1990; 322: 1045.
33. Rudolph P, Alm P, Heidebrccht HJ et al. Immonologic proliferation marker Kİ-S2 as prognostic indicator for lymph node-negative breast cancer. J Natl Cancer Inst 1999; 91:271.
34. Kromun N, Jenscn MB, VVohlfahrt J et al. Factors influ-encing the effcct of age on prognosis in breast cancer: population based study. Commentary: much stili to lcarn about relations bctween tumour biology, prognosis, and treatment outeome in early breast cancer. BMJ 2000; 320:474.
35. Veronese SM, Gambacorta M, Gottardi O et al. Proliferation index as a prognostic marker in breast cancer. Cancer 1993; 71: 3926.

Thank you for copying data from http://www.arastirmax.com